AbbVie Inc.

NYSE:ABBV Voorraadrapport

Marktkapitalisatie: US$446.5b

AbbVie Toekomstige groei

Future criteriumcontroles 4/6

AbbVie zal naar verwachting groeien in winst en omzet met respectievelijk 28.3% en 6.4% per jaar. De winst per aandeel zal naar verwachting groeien met 27.3% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 230.1% zijn.

Belangrijke informatie

28.3%

Groei van de winst

27.33%

Groei van de winst per aandeel

Biotechs winstgroei25.1%
Inkomstengroei6.4%
Toekomstig rendement op eigen vermogen230.09%
Dekking van analisten

Good

Laatst bijgewerkt09 Jul 2026

Recente toekomstige groei-updates

Recent updates

Narratiefupdate • Jun 23

ABBV: Future Returns Will Hinge On Apogee Deal And Immunology Pipeline

Analysts have made only a modest adjustment to AbbVie’s fair value narrative, reflecting a slightly higher discount rate and updated views on margins and long term P/E in light of the proposed $10.9 billion Apogee Therapeutics deal and its implications for competition and atopic dermatitis market potential. Analyst Commentary Recent research on AbbVie around the proposed US$10.9b Apogee Therapeutics acquisition highlights a mix of optimism about growth opportunities in immunology and atopic dermatitis, alongside caution about execution risk, competition, and valuation.
Seeking Alpha • Jun 19

AbbVie: Immunology Cash Flow Funds Oncology Expansion

Summary I continue to cover AbbVie with a 'Buy' rating due to its R&D achievements. So, in the past 3 months, Decnupaz and Skinvive by Juvederm have received FDA approvals. Moreover, a week ago, AbbVie reported promising results from the Phase 3 CLL14 trial for the treatment of chronic lymphocytic leukemia patients. Meanwhile, Venclexta generated $770 million in revenue for AbbVie in Q1, up 15.8% year-over-year and 8.5% QoQ. Also, inthis article, you will know why the superiority of UCB's Bimzelx over Skyriziin the Phase 3 BE BOLD study doesn't threaten the sales growth of AbbVie's IL-23 inhibitor. Read the full article on Seeking Alpha
Analyseartikel • Jun 16

AbbVie (ABBV) Stock Could Be 12.6% Undervalued After CLL14 Trial Update

AbbVie (ABBV) is back in focus after releasing nine year final results from its Phase 3 CLL14 trial, where a fixed duration venetoclax plus obinutuzumab regimen improved progression free survival in untreated CLL patients. See our latest analysis for AbbVie. The latest CLL14 update lands after a mixed few sessions for AbbVie, with the share price slipping 2.7% on the day to $221.59, while still showing a 5.3% 30 day share price return and a 19.9% one year total shareholder return that points...
Narratiefupdate • Jun 06

ABBV: Future Returns Will Depend On Expanding Immunology And IBD Pipeline Execution

AbbVie’s updated analyst price target edges higher to $253.55 from $249.43 as analysts factor in slightly higher profit margin assumptions, modestly lower revenue growth expectations, a reduced discount rate, and a somewhat lower future P/E multiple, with recent research highlighting the depth of the inflammatory bowel disease pipeline and broader R&D optionality. Analyst Commentary Recent Street research on AbbVie shows a mix of optimism and caution, with multiple price target revisions clustered within a relatively tight range and commentary that keeps attention on the inflammatory bowel disease pipeline and broader R&D portfolio.
Analyseartikel • May 15

We Think You Can Look Beyond AbbVie's (NYSE:ABBV) Lackluster Earnings

The market was pleased with the recent earnings report from AbbVie Inc. ( NYSE:ABBV ), despite the profit numbers being...
Narratiefupdate • Apr 23

ABBV: Future Returns Will Rely On Immunology Expansion And Operating Leverage Execution

Analysts made a small upward adjustment to AbbVie’s fair value estimate to about $249. The modest change reflects a mix of slightly higher assumed discount rates and future P/E multiples, alongside recent shifts in Street price targets, including both raises and trims from firms such as Piper Sandler, Guggenheim, Cantor Fitzgerald, Evercore ISI, Citi and UBS, as well as fresh bullish initiations from Canaccord, RBC Capital and Barclays.
Narratiefupdate • Apr 08

ABBV: Future Returns Will Hinge On Immunology Encore And Operating Leverage Execution

Analysts have made a modest upward adjustment to AbbVie’s price target, reflecting updated views on its immunology pipeline potential, operating leverage, and the ongoing debate about whether recent share underperformance and selloffs adequately reflect competitive risks. Analyst Commentary Recent research on AbbVie highlights a split view, with some analysts focusing on the upside from the immunology pipeline and operating leverage, while others point to valuation and competitive questions after a period of share underperformance.
Narratiefupdate • Mar 24

ABBV: Future Returns Will Hinge On Immunology Encore Outweighing Competitive Concerns

Narrative Update The analyst price target for AbbVie has been adjusted slightly higher to reflect a fair value move to about $249. Analysts point to early stage indication expansion, operating leverage potential, and ongoing immunology pipeline developments, even as some firms flag emerging competition and a more balanced risk and reward profile.
Narratiefupdate • Mar 10

ABBV: Future Returns Will Depend On Immunology Encore And Deal Optionality Uncertainty

The analyst price target for AbbVie edges higher to align with our fair value shift from $248.29 to $248.86, as analysts highlight ongoing indication expansion in immunology, potential operating leverage, and multiple expansion drivers, even as some firms note emerging competition and a more balanced risk and reward profile. Analyst Commentary Recent research on AbbVie reflects a split view, with some analysts pointing to upside tied to immunology growth and pipeline execution, while others flag competition risk and a more balanced risk and reward profile at current levels.
Narratiefupdate • Feb 22

ABBV: Future Returns Will Rely On Immunology Encore And Evolving Deal Optionality

Our updated AbbVie narrative reflects a modest price target increase to about $248 per share, as analysts point to potential operating leverage, room for P/E multiple expansion, and a pipeline of proof-of-concept and immunology programs that could support slightly higher revenue growth assumptions, even as margin expectations are trimmed. Analyst Commentary Recent research shows a mix of optimism and caution around AbbVie, with several firms adjusting price targets and ratings as they reassess execution risks, competitive pressures, and the potential impact of the pipeline on valuation.
Narratiefupdate • Feb 07

ABBV: Future Returns Will Depend On Immunology Pipeline Clarity And M&A Uncertainty

Analysts have trimmed their price targets for AbbVie by a small amount. This reflects slightly lower revenue growth and P/E assumptions, while also incorporating a modestly higher profit margin and recent mixed research views around competition and pipeline visibility.
Narratiefupdate • Jan 24

ABBV: Future Returns Will Hinge On Post-Humira Immunology And Deal Optionality

Analysts have nudged their price target for AbbVie slightly higher to reflect a fair value estimate of about $245 per share, supported by updated assumptions for revenue growth, profit margins, and a modestly lower future P/E. Recent research highlights both increased price targets and more cautious views around competition and the sustainability of outperformance in key immunology drugs.
Narratiefupdate • Jan 09

ABBV: Future Returns Will Depend On Post-Humira Immunology And Pipeline Execution

Analysts have trimmed their AbbVie fair value estimate by about $0.10 per share to roughly $244.56. This reflects a mix of slightly higher risk assumptions, modestly adjusted revenue and margin expectations, and a more balanced set of views after recent downgrades and price target changes that suggest outperformance is already well reflected in the current share price.
Analyseartikel • Jan 08

AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73

AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 17th of February to...
Narratiefupdate • Dec 21

ABBV: Future Returns Will Hinge On Post-Humira Immunology And Pipeline Execution

Analysts have nudged our AbbVie fair value estimate slightly higher, from $243.55 to $244.68. This reflects modestly stronger long term revenue growth expectations for key immunology franchises and pipeline assets, partially offset by slightly lower margin assumptions and a broadly constructive but mixed backdrop of recent price target revisions and rating changes across the Street.
Narratiefupdate • Dec 07

ABBV: Future Performance Will Depend On Extended Exclusivity And Pipeline Execution

Analysts have nudged their average price target on AbbVie modestly higher to reflect a wave of target increases into the mid 240s to low 260s dollar range, supported by stronger visibility into Skyrizi and Rinvoq driven growth, extended Rinvoq exclusivity, and a more favorable large cap biopharma backdrop despite mixed ratings changes. Analyst Commentary Recent research paints a generally constructive picture on AbbVie, with most price target revisions skewing higher even as some firms move to the sidelines.
Analyseartikel • Dec 02

AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73

The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.73 on the 17th of...
Narratiefupdate • Nov 23

ABBV: Future Performance Will Depend On Pipeline Expansion And Patent Protections

AbbVie’s analyst price target has increased modestly from $241.29 to $243.55. Analysts cite resilient performance in immunology products, extended Rinvoq exclusivity, and improving fundamentals as key drivers of sentiment.
Analyseartikel • Nov 18

AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73

The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.73 on the 17th of...
Narratiefupdate • Nov 08

ABBV: Future Performance Will Reflect Balance Between Patent Wins and Product Pressures

AbbVie's analyst price target has risen modestly from $237.48 to $241.29. Analysts cite resilient fundamentals and long-term patent settlements, which help offset recent industry downgrades and softer performance in some business units.
Narratiefupdate • Oct 25

Continued Expansion in Neuroscience and Immunology Will Drive Leadership Beyond 2025

AbbVie's analyst price target has been raised from approximately $233 to $237 per share. Analysts cite ongoing revenue growth, improved margins, and extended exclusivity for key products as the main drivers behind the upward revision.
Narratiefupdate • Oct 11

Expanding Immunology And Neuroscience Will Reshape Global Healthcare

AbbVie's analyst price target has increased significantly, rising from $227 to $233 per share. Analysts cite recent positive developments in patent settlements and stronger-than-expected performance across key growth drivers as the main rationales.

Winst- en omzetgroeiprognoses

NYSE:ABBV - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202878,13221,85534,65033,18019
12/31/202772,73419,02333,57830,27624
12/31/202667,23514,35330,82125,38824
3/31/202662,8193,59519,98021,224N/A
12/31/202561,1604,18617,81619,030N/A
9/30/202559,6442,34819,68420,860N/A
6/30/202558,3283,72318,23919,283N/A
3/31/202557,3674,15515,38516,401N/A
12/31/202456,3344,23817,83218,806N/A
9/30/202455,5335,08115,62316,511N/A
6/30/202455,0005,29817,78018,638N/A
3/31/202454,4035,95121,89122,686N/A
12/31/202354,3184,82022,06222,839N/A
9/30/202355,1386,47124,72925,514N/A
6/30/202356,0238,63524,79925,542N/A
3/31/202356,7417,53523,52024,228N/A
12/31/202258,05411,78224,24824,943N/A
9/30/202257,81913,34321,92122,590N/A
6/30/202257,34912,56922,21422,923N/A
3/31/202256,72512,40722,04722,808N/A
12/31/202156,19711,46821,99022,777N/A
9/30/202155,1697,46521,67722,556N/A
6/30/202153,7296,59919,57220,451N/A
3/31/202150,1955,09217,78918,650N/A
12/31/202045,8044,55616,79017,588N/A
9/30/202040,6507,32415,32716,009N/A
6/30/202036,2276,90614,11514,734N/A
3/31/202034,0578,39513,55214,122N/A
12/31/201933,2667,842N/A13,324N/A
9/30/201932,8673,232N/A13,441N/A
6/30/201932,6244,093N/A13,410N/A
3/31/201932,6475,333N/A13,799N/A
12/31/201832,7535,657N/A13,427N/A
9/30/201832,1877,531N/A12,619N/A
6/30/201830,9466,419N/A11,366N/A
3/31/201829,6126,352N/A10,503N/A
12/31/201728,2165,283N/A9,960N/A
9/30/201727,2736,615N/A8,917N/A
6/30/201726,7106,582N/A7,100N/A
3/31/201726,2186,278N/A7,015N/A
12/31/201625,6385,923N/A7,041N/A
9/30/201625,2426,048N/A7,463N/A
6/30/201624,7545,690N/A8,164N/A
3/31/201623,7775,448N/A8,078N/A
12/31/201522,8595,118N/A7,535N/A
9/30/201521,9112,790N/A4,994N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei ABBV ( 28.3% per jaar) ligt boven de spaarquote ( 3.5% ).

Winst versus markt: De winst van ABBV ( 28.3% per jaar) zal naar verwachting sneller groeien dan de US markt ( 18.2% per jaar).

Hoge groeiwinsten: De winst van ABBV zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van ABBV ( 6.4% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 12.9% per jaar).

Hoge groei-inkomsten: De omzet van ABBV ( 6.4% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen ABBV zal naar verwachting over 3 jaar zeer hoog zijn ( 230.1 %).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/07/09 04:01
Aandelenkoers aan het einde van de dag2026/07/09 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

AbbVie Inc. wordt gevolgd door 51 analisten. 24 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
David ToungArgus Research Company
Emily FieldBarclays
Luisa HectorBerenberg